Category: Psychedelics
-
Core One Labs (COOL.C) takes their artificial psilocybin research to UBC
Core One Labs (COOL.C) subsidiary, Vocan Biotechnologies, and the University of British Columbia (UBC), came to terms on a collaborative research agreement today, according to a press release. The collaboration gives Vocan access to a well-funded, world-class research facility and team to enhance their position in the nascent psychedelic medicine space, especially given the increasing…
-
Cybin (CYBN.NE) demonstrates Proof of Concept on CYB003 and CYB004 psychedelic molecules
Cybin (CYBN.NE) announced that they have successfully demonstrated Proof of Concept for their deuterated tryptamine programs, CYB003 and CYB004. The Proof of Concept revolves around the duration of psilocybin. A normal psilocybin experience will last around six hours, and can take up to an hour to begin. However, in their press release, Cybin notes that…
-
Core One Labs (COOL.C) begins work on proprietary DMT production
Core One Labs’ (COOL.C) wholly-owned subsidiary Vocan Biotechnologies has initiated the design and engineering of a proprietary enzymatic production system for API-grade N,N-dimethyltryptamine, commonly known as DMT. DMT, also known as the “spirit molecule”, is a naturally occurring psychedelic and is an active component in ayahuasca. It plays an important role in various rites of…
-
Sixth Wave Innovations (SIXW.C) Enters LOI With Halucenex Life Sciences
Sixth Wave Innovations (SIXW.C) entered into a non-binding letter of intent (LOI) with Halucenex Life Sciences, a soon to be wholly-owned subsidiary of Cresco Pharma. According to the terms outlined in the LOI, Sixth Wave will utilize its Affinity™ in collaboration with Halucenex to explore the separation of compounds such as psilocybin, baeocystin, and others…
-
Cybin (CYBN.NE) establishes Clinical Advisory Board as they gear up for trials
Cybin (CYBN.NE) announced they are forming a Clinical Advisory Board, which will be chaired by Alex Belser, Cybin’s Chief Clinical Officer. The board will consist of Belser (PhD), Maurizio Fava (MD), Lynn Marie Morski (DM) and Anthony Back (MD). All members of the board have professional experience in either medicine or research. Fava, the Psychiatrist-in-Chief…
-
Delic Holdings (DELC.C) gives Q1, 2021 update on its psychedelic business divisions
On February 5th, 2021 DELIC announced the acquisition of KIC, who over the last 3 years have overseen 4,000 ketamine infusion treatments, while revenues increase to over USD $1.5 million.
-
Pure Extracts (PULL.C) to enter U.S. market through JV in Michigan
If the LOI becomes a binding contract, Pure Extracts will contribute “a mix of equipment and cash to the venture”, which will allow the partners to rapidly scale-up to meet the rising demand for recreation cannabis concentrates and edibles throughout Michigan.
-
What are psychedelics companies like Psyense (PSYG.C), Havn (HAVN.C), Canbud (CBDX.C) and Field Trip (FTRP.C) all doing in Jamaica?
Shroom tea Jamaica is one of the few countries in the world where the sale and consumption of psilocybin is legal, and through my DD, it’s incredibly easy to attain. The country isn’t new to foreigners tripping there, tourists have been visiting the island for decades for its famous magic mushroom teas. For people who…
-
How Cybin (CYBN.NE) is integrating new brain imaging technology with psychedelics
Shamans among the machines In his 1999 lecture titled ‘Shamans Among the Machines’ Terence McKenna pointed out that “as far as people and machines are concerned, it was Ludwig von Bertalanffy who said in his book General Systems Theory: ‘people are not machines, but in every opportunity where they are allowed to behave like machines,…